Skip to main content

Myriad, BioMarin Expand Collaboration

NEW YORK (GenomeWeb) – Myriad Genetics today said it and BioMarin Pharmaceutical have expanded their collaboration to use Myriad's companion diagnostic test to identify patients who may benefit from the anti-cancer drug talazoparib. 

Under the terms of the agreement, BioMarin will use Myriad's myChoice HRD test to identify patients with metastatic breast, ovarian, and potentially other tumor types who may be candidates for talazoparib, an investigational poly-ADP ribose polymerase inhibitor under development by BioMarin. The companies will collaborate under US Food and Drug Administration regulations and guidelines to develop and possibly seek regulatory approval of talazoparib and myChoice HRD. 

Financial and other terms were not disclosed. 

Today's deal builds on a relationship between Myriad and BioMarin started in 2013 when they reached a deal for the use of Myriad's BRACAnalysis CDx in the pivotal Phase III EMBRACA and Phase II ABRAZO clinical study of talazoparib for advanced or metastatic breast cancer patients with BRCA mutations.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.